clinical trial
collaboration
Novocure announces new clinical trial collaboration with MSD.
Learn more
HEPANOVA
trial update
Novocure has enrolled the last patient in the HEPANOVA trial testing Tumor Treating Fields in combination with sorafenib in advanced liver cancer.
Learn more
Novocure
news
Over 100 physicians from more than 50 cancer treatment centers in the U.S. are now certified to prescribe Novocure’s cancer therapy for malignant pleural mesothelioma.
Learn More
only the
beginning
Novocure’s 2019 Annual Report celebrates the 20th anniversary of the company, telling the stories of 20 significant milestones throughout the last two decades.
Learn More
Novocure’s response to COVID-19
Important information for our patients, caregivers and providers
Learn More
the story
of Novocure
In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with nearly 600 employees and operations in the U.S., Europe and Asia.
Learn More
we can leverage physics to fight cancer
Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and potentially causing cancer cells to die.
OUR THERAPY
explore our clinical pipeline
Our research shows that Tumor Treating Fields have an antimitotic effect in more than 18 solid tumor types in culture and in eight in vivo tumor models.
OUR PIPELINE
we are dedicated to improving the lives of cancer patients
Patients remain at the heart of the work we do every day. Learn more about our patients, their families and the people working to deliver patient-forward therapies to treat cancer.
PATIENT-FORWARD